Fibrinogen plasma concentration is an independent marker of haemodynamic impairment in chronic thromboembolic pulmonary hypertension

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Hennigs, Jan K ^a,c   Baumann, Hans Jörg ^a   Lüneburg, Nicole ^a   Quast, Gesine ^a   Harbaum, Lars ^a   Heyckendorf, Jan ^a   Sydow, Karsten ^a   Schulte Hubbert, Bernhard ^b   Halank, Michael ^b   Klose, Hans ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; FIBRINOGEN;

AGED; BLOOD; CHRONIC DISEASE; FEMALE; FOLLOW UP; HEMODYNAMICS; HUMAN; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE;

EID: 84899634774     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04808     Document Type: Article

References (35)

1. Lang, I. M., Pesavento, R., Bonderman, D. & Yuan, J. X.-J. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur. Respir. J. 41, 462-468 (2013).
2. Bonderman, D. et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 33, 325-331 (2008).
3. Miniati, M. et al. Fibrin Resistance to Lysis in Patients with Pulmonary Hypertension Other Than Thromboembolic. Am. J. Respir. Crit. Care Med. 181, 992-996 (2010).
4. Galie, N. & Kim, N. H. S. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 3, 571-576 (2006). (Pubitemid 44411622)
5. Skoro-Sajer, N. et al. Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 176, 1154-1160 (2007). (Pubitemid 350223762)
6. Pepke-Zaba, J. et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 124, 1973-1981 (2011).
7. Price, L. C. et al. Inflammation in pulmonary arterial hypertension. Chest 141, 210-221 (2012).
8. Quarck, R., Nawrot, T., Meyns, B. & Delcroix, M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 53, 1211-1218 (2009).
9. Davalos, D. & Akassoglou, K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 34, 43-62 (2012).
10. Reinhart, W. H. Fibrinogen-marker or mediator of vascular disease? Vasc Med 8, 211-216 (2003).
11. Can, M. M. et al. Enhanced hemostatic indices in patients with pulmonary arterial hypertension: An observational study. Thromb. Res. 126, 280-282 (2010).
12. The Emerging Risk Factors Collaboration. C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. N. Engl. J. Med. 367, 1310-1320 (2012).
13. Huber, K. et al. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am. J. Respir. Crit. Care Med. 150, 929-933 (1994). (Pubitemid 24318015)
14. Welsh, C. H., Hassell, K. L., Badesch, D. B., Kressin, D. C. & Marlar, R. A. Coagulation and fibrinolytic profiles in patients with severe pulmonary hypertension. Chest 110, 710-717 (1996). (Pubitemid 27009296)
15. Eisenberg, P. R. et al. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. Circulation 82, 841-847 (1990). (Pubitemid 20316735)
16. Morris, T. A. et al. Fibrin derived from patients with chronic thromboembolic pulmonary hypertension is resistant to lysis. Am. J. Respir. Crit. Care Med. 173, 1270-1275 (2006). (Pubitemid 43848399)
17. Suntharalingam, J. et al. Fibrinogen Aalpha Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 31, 736-741 (2008).
18. Morris, T. A. et al. High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood 114, 1929-1936 (2009).
19. Lelakowski, J. et al. Effect of selected prothrombotic and proinflammatory factors on the incidence of venous thrombosis after pacemaker implantation. Kardiol Pol 70, 260-267 (2012).
20. Watters, J. M. et al. Splenectomy leads to a persistent hypercoagulable state after trauma. Am. J. Surg. 199, 646-651 (2010).
21. Vayá, A. et al. Erythrocyte aggregability and AB0 blood groups. Clin. Hemorheol. Microcirc. 41, 67-72 (2009).
22. Sailer, T. et al. Inflammation in patients with lupus anticoagulant and implications for thrombosis. J. Rheumatol. 32, 462-468 (2005). (Pubitemid 40381416)
23. Çakal, B. et al. Homocysteine and fibrinogen changes with L-thyroxine in subclinical hypothyroid patients. J Korean Med Sci 22, 431-435 (2007).
24. Edwards, R. L. et al. Abnormalities of blood coagulation tests in patients with cancer. Am. J. Clin. Pathol. 88, 596-602 (1987). (Pubitemid 18014618)
25. Langer, F. et al. Cytokine response to pulmonary thromboendarterectomy. Chest 126, 135-141 (2004). (Pubitemid 38943129)
26. Kimura, H. et al. Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 164, 319-324 (2001). (Pubitemid 34001302)
27. Damås, J. K. et al. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation 110, 999-1005 (2004). (Pubitemid 39136216)
28. Wynants, M. et al. Effects of C-reactive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension. Eur. Respir. J. 40, 886-894 (2012).
29. Firth, A. L. et al. Chronic exposure to fibrin and fibrinogen differentially regulates intracellular Ca21 in human pulmonary arterial smooth muscle and endothelial cells. Am J Physiol Lung Cell Mol Physiol. 296, L979-86 (2009).
30. Sen, U. et al. Fibrinogen-induced endothelin-1 production from endothelial cells. Am. J. Physiol., Cell Physiol. 296, C840-7 (2009).
31. Hoeper, M. M., Sosada, M. & Fabel, H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur. Respir. J. 12, 1446-1449 (1998). (Pubitemid 29011445)
32. Petzelbauer, P. et al. The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury. Nat Med 11, 298-304 (2005). (Pubitemid 40460558)
33. Eritsland, J., Seljeflot, I., Arnesen, H., Smith, P. & Westvik, A. B. Effects of longterm treatment with warfarin on fibrinogen, FPA, TAT, and D-dimer in patients with coronary artery disease. Thromb. Res. 66, 55-60 (1992).
34. Prisco, D. et al. Effect of low-dose heparin on fibrinogen levels in patients with chronic ischemic heart disease. Int. J. Clin. Lab. Res. 28, 170-173 (1998).
35. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 34, 1219-1263 (2009).